Despite being on the US market since 1989 – initially for medical uses like strabismus and blepharospasm, and later for ...

Credit unions across the country saw member savings and loans, particularly mortgages, increase over the latest financial ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

Our beauty team has tried and tested a range of the best wrinkle-busting creams, serums and fillers on the market so you ...

Biohacker Bryan Johnson uses Cialis, shockwave therapy, and Botox to boost nighttime erections, claiming they reflect overall ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

Disgraced former Republican politician George Santos, who was expelled from the US Congress for using stolen donor cash to bankroll a lavish lifestyle including designer suits, Botox and subscriptions ...

HELLO!'s Second Act is a newsletter for women in midlife and beyond. It's completely free to sign up and is a one-stop-shop ...

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

A mother of two in New York died weeks after receiving a botched butt implant procedure in the home of a man who was performing medical procedures without a license.

AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.